Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme -- Ignore unavailable to you. Want to Upgrade?

To: Jay Letterman who wrote (8404)	8/18/1998 9:49:00 AM
From: Leman	Read Replies (1) \| Respond to of 8798

Tuesday August 18, 8:42 am Eastern Time Company Press Release SOURCE: Biomerica, Inc. Biomerica Receives New Patent for Test to Predict Diabetes Years Before Onset NEWPORT BEACH, Calif., Aug. 18 /PRNewswire/ -- Biomerica, Inc. (Nasdaq: BMRA - news) announced today the U.S. Patent and Trademark Office has issued the company a key patent for its diagnostic kit that provides clinicians a very early warning that a patient is predisposed to developing type I (insulin dependent) diabetes. By detecting Islet Cell Autoantibodies (ICA), the test has the ability to identify individuals with a high risk of developing type I diabetes several years before actual onset of the disease. More than 15 million Americans -- one in 20 -- are impacted by diabetes. The total indirect and direct costs attributed to diabetes in the U.S. is over $92 billion. ''Biomerica has the most comprehensive product line available to detect individuals predisposed to developing type I diabetes,'' said Zackary Irani, Chief Executive Officer. Irani added that the company has a corporate strategy of carefully protecting its intellectual property and that this patent is an important part of that strategy. Biomerica's diagnostic test, which is marketed internationally under the trade name Isletest(R)-ICA, is an important tool in detecting this disease at a very early stage. The combination of early detection and treatment could greatly increase patient survival while at the same time reducing health care costs. The test requires only a blood sample and can be performed at almost any clinical laboratory. Irani said Biomerica plans to introduce the product to the U.S. market following clinical trials necessary to receive U.S. Food and Drug Administration clearance. An average of approximately 800,000 new cases of diabetes are diagnosed each year. Complications of diabetes include heart disease, stroke, high blood pressure, blindness, kidney disease, and amputation. Type I diabetes is believed to account for up to 15% of all diagnosed cases of the disease. BIOMERICA (Nasdaq: BMRA - news) is a global medical company devoted to developing, manufacturing and marketing advanced medical diagnostic products for the early detection of diseases. The products are used in hospitals, physician's offices and in the home for self testing. Except for historical information contained herein, the statements in this Press Release are forward-looking statements that are made pursuant to the safe harbor provisions of The Private Securities Litigation Reform act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, the continued demand for the Company's products, availability of raw materials and the state of the economy. These and other risks are described in the Company's Annual Report on Form 10-KSB and in the Company's other filings with the Securities and Exchange Commission. SOURCE: Biomerica, Inc.